FLASHIda enables intelligent data acquisition for top-down proteomics to boost proteoform identification counts
Source check: Source checked. Not independent scientific confirmation.
Finding: In E. coli lysate, FLASHIda increased unique proteoform identifications from 800 to 1,500 or achieved a near-identical count in one-third the instrument time versus standard data-dependent acquisition. The result is an instrument-specific proteomics analysis; broader biological or clinical consequences are not established.
Technology: FLASHIda uses learned acquisition to select high-quality proteoform precursors in real time for top-down proteomics.
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- FLASHIda uses learned acquisition to select high-quality proteoform precursors in real time for top-down proteomics.
- Test and result
- In E. coli lysate, FLASHIda increased unique proteoform identifications from 800 to 1,500 or achieved a near-identical count in one-third the instrument time versus standard data-dependent acquisition.
- Limitation / still unknown
- The result is an instrument-specific proteomics analysis; broader biological or clinical consequences are not established.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://doi.org/10.1038/s41467-022-31922-z
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.